Clinical Trial Update: A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients [Phase 3]

View source ↗

Summary

A Phase III randomized trial targeting CLDN18.2 in patients with unresectable, locally advanced gastric cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Snippet

Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd | Conditions: Gastric Adenocarcinoma | Phase 3 | Status: RECRUITING